(Invited) Overview of the U.S. Department of Energy’s National Laboratory Consortia to Improve Fuel Cells for Heavy-Duty Applications

2021 ◽  
Vol MA2021-02 (44) ◽  
pp. 1332-1332
Author(s):  
Gregory Kleen ◽  
Dimitrios Papageorgopoulos ◽  
William T Gibbons ◽  
Donna Ho ◽  
David Peterson ◽  
...  

2004 ◽  
Vol 1 (1) ◽  
pp. 18-20 ◽  
Author(s):  
Mark C. Williams ◽  
Bruce R. Utz ◽  
Kevin M. Moore

The U.S. Department of Energy’s (DOE) Office of Fossil Energy’s (FE) National Energy Technology Laboratory (NETL), in partnership with private industries, is leading the development and demonstration of high efficiency solid oxide fuel cells (SOFCs) and fuel cell turbine hybrid power generation systems for near term distributed generation (DG) markets with an emphasis on premium power and high reliability. NETL is partnering with Pacific Northwest National Laboratory (PNNL) in developing new directions in research under the Solid-State Energy Conversion Alliance (SECA) initiative for the development and commercialization of modular, low cost, and fuel flexible SOFC systems. The SECA initiative, through advanced materials, processing and system integration research and development, will bring the fuel cell cost to $400 per kilowatt (kW) for stationary and auxiliary power unit (APU) markets. The President of the U.S. has launched us into a new hydrogen economy. The logic of a hydrogen economy is compelling. The movement to a hydrogen economy will accomplish several strategic goals. The U.S. can use its own domestic resources—solar, wind, hydro, and coal. The U.S. uses 20 percent of the world’s oil but has only 3 percent of resources. Also, the U.S. can reduce green house gas emissions. Clear Skies and Climate Change initiatives aim to reduce carbon dioxide (CO2), nitrogen oxides (NOx), and sulfur dioxide (SO2) emissions. SOFCs have no emissions, so they figure significantly in these DOE strategies. In addition, DG—SOFCs, reforming, energy storage—has significant benefit for enhanced security and reliability. The use of fuel cells in cars is expected to bring about the hydrogen economy. However, commercialization of fuel cells is expected to proceed first through portable and stationary applications. This logic says to develop SOFCs for a wide range of stationary and APU applications, initially for conventional fuels, then switch to hydrogen. Like all fuel cells, the SOFC will operate even better on hydrogen than conventional fuels. The SOFC hybrid is a key part of the FutureGen plants. FutureGen is a major new Presidential initiative to produce hydrogen from coal. The highly efficient SOFC hybrid plant will produce electric power and other parts of the plant could produce hydrogen and sequester CO2. The hydrogen produced can be used in fuel cell cars and for SOFC DG applications.





Neurology ◽  
2021 ◽  
pp. 10.1212/WNL.0000000000012199
Author(s):  
Douglas J. Lanska

In 2014, American neurologist and Nobel laureate Stanley Prusiner reported that microbiologist Clarence Joseph Gibbs at the U.S. National Institutes of Health had intentionally, systematically, and mischievously used the eponym Creutzfeldt-Jakob disease (CJD), rather than Jakob-Creutzfeldt disease (JCD), because of the correspondence with Gibbs’ own initials to imply “Clarence Joseph’s disease.”The present study examines temporal trends in the use of “Creutzfeldt-Jakob” and “Jakob-Creutzfeldt” in scientific articles and monographs from 1946 to 2019 to assess whether there was a “Clarence J. Gibbs’ effect” that influenced the general use of a specific eponym by the scientific community. During Gibbs’ period of publication on CJD, there was an abrupt, dramatic, and steady increase in use of the CJD eponym while use of the JCD eponym remained at a low level. In the period after Gibbs ceased to publish, there was a corresponding marked fall-off in use of the CJD eponym. Surviving collaborators thought Gibbs may have been joking, but in 1991 Gibbs had admitted what Prusiner reported. Regardless of motive, Gibbs strongly influenced the preferred eponym for this human prion disease by: (1) publishing a seminal and highly referenced initial paper in a high-profile journal; (2) sustained output of further important studies published in high-quality journals over more than 30 years; (3) professional affiliation with an esteemed national laboratory where he worked with a large number of high-profile colleagues; and (4) extensive collaborations with a large number of colleagues, who published multiple further papers using the eponym Gibbs preferred.



Sign in / Sign up

Export Citation Format

Share Document